TY - JOUR
T1 - Anti-MET targeted therapy has come of age
T2 - The first durable complete response with MetMAb in metastatic gastric cancer
AU - Feng, Yan
AU - Ma, Patrick C.
PY - 2011/12
Y1 - 2011/12
N2 - The MET/hepatocyte growth factor (HGF) signaling pathway plays important roles in oncogenesis and tumor progression in a variety of human cancers. MET/HGF drives an invasive signaling program that can be dysregulated in human cancers through a number of activating mechanisms, including mutations, overexpression, amplification, alternative splicing, and HGF ligand-induced autocrine/paracrine loop signaling. As a testimony of MET-targeting therapeutics is beginning to come to clinical fruition, Catenacci and colleagues report the first case of durable complete response under an anti-MET receptor monoclonal antibody, MetMAb, in a patient with chemotherapy-refractory, advanced gastric cancer metastatic to the liver, found to have high MET gene polysomy and remarkably high serum HGF level. Serum and tissue studies also revealed predictive biomarkers for therapeutic response to MET inhibition.
AB - The MET/hepatocyte growth factor (HGF) signaling pathway plays important roles in oncogenesis and tumor progression in a variety of human cancers. MET/HGF drives an invasive signaling program that can be dysregulated in human cancers through a number of activating mechanisms, including mutations, overexpression, amplification, alternative splicing, and HGF ligand-induced autocrine/paracrine loop signaling. As a testimony of MET-targeting therapeutics is beginning to come to clinical fruition, Catenacci and colleagues report the first case of durable complete response under an anti-MET receptor monoclonal antibody, MetMAb, in a patient with chemotherapy-refractory, advanced gastric cancer metastatic to the liver, found to have high MET gene polysomy and remarkably high serum HGF level. Serum and tissue studies also revealed predictive biomarkers for therapeutic response to MET inhibition.
UR - http://www.scopus.com/inward/record.url?scp=84865758495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865758495&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-11-0289
DO - 10.1158/2159-8290.CD-11-0289
M3 - Article
C2 - 22586678
AN - SCOPUS:84865758495
SN - 2159-8274
VL - 1
SP - 550
EP - 554
JO - Cancer Discovery
JF - Cancer Discovery
IS - 7
ER -